CL2017001923A1 - Derivados de 9h-pirrolo-dipiridina - Google Patents

Derivados de 9h-pirrolo-dipiridina

Info

Publication number
CL2017001923A1
CL2017001923A1 CL2017001923A CL2017001923A CL2017001923A1 CL 2017001923 A1 CL2017001923 A1 CL 2017001923A1 CL 2017001923 A CL2017001923 A CL 2017001923A CL 2017001923 A CL2017001923 A CL 2017001923A CL 2017001923 A1 CL2017001923 A1 CL 2017001923A1
Authority
CL
Chile
Prior art keywords
pyrrolo
derivatives
dipyridine
dipyridine derivatives
radiopharmactics
Prior art date
Application number
CL2017001923A
Other languages
English (en)
Inventor
Yogesh Anil Sabnis
Joël Mercier
Laurent Provins
Celine Vermeiren
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CL2017001923A1 publication Critical patent/CL2017001923A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

<p>LA INVENCIÓN SE REFIERE A DERIVADOS DE 9H-PIRROLO-DIPIRIDINA DE LA FORMULA I, PROCESOS PARA PREPARARLOS, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO COMO RADIOFÁRMACOS EN PARTICULAR COMO AGENTES DE FORMACIÓN DE IMÁGENES PARA LA DETECCIÓN DE AGREGADOS TAU.</p>
CL2017001923A 2015-02-02 2017-07-27 Derivados de 9h-pirrolo-dipiridina CL2017001923A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15153448 2015-02-02

Publications (1)

Publication Number Publication Date
CL2017001923A1 true CL2017001923A1 (es) 2018-02-16

Family

ID=52477553

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001923A CL2017001923A1 (es) 2015-02-02 2017-07-27 Derivados de 9h-pirrolo-dipiridina

Country Status (17)

Country Link
US (2) US20180022748A1 (es)
EP (1) EP3253762B1 (es)
JP (1) JP6579670B2 (es)
KR (1) KR102621513B1 (es)
CN (1) CN107207508B (es)
AU (1) AU2016214537B2 (es)
BR (1) BR112017016311A2 (es)
CA (1) CA2973648C (es)
CL (1) CL2017001923A1 (es)
DK (1) DK3253762T3 (es)
EA (1) EA036518B1 (es)
ES (1) ES2875734T3 (es)
IL (1) IL253381B (es)
MX (1) MX2017009505A (es)
MY (1) MY191590A (es)
SG (1) SG11201705727TA (es)
WO (1) WO2016124508A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110046378A1 (en) 2008-02-14 2011-02-24 Siemens Medical Solutions Usa, Inc. Novel Imaging Agents for Detecting Neurological Dysfunction
US10865207B2 (en) 2016-07-22 2020-12-15 Ac Immune S.A. Compounds for imaging Tau protein aggregates
CN109475648B (zh) 2016-07-22 2023-03-14 Ac免疫有限公司 用于成像tau蛋白聚集体的化合物
SI3510031T1 (sl) * 2016-09-09 2021-03-31 F. Hoffmann-La Roche Ag Postopek za pripravo 2-(6-nitropiridin-3-il)-9H-dipirido(2,3-b;3',4'-d)pirola
KR20230127371A (ko) * 2016-11-01 2023-08-31 아비나스 오퍼레이션스, 인코포레이티드 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
JP7282028B2 (ja) 2017-06-02 2023-05-26 富士フイルム富山化学株式会社 脳萎縮予防または治療剤
EP3636262A4 (en) 2017-06-02 2020-06-10 FUJIFILM Toyama Chemical Co., Ltd. AGENT FOR PREVENTING OR TREATING ALZHEIMER-LIKE DEMENTIA
BR112019024878A2 (pt) * 2017-06-02 2020-06-16 Fujifilm Toyama Chemical Co., Ltd. Agente para prevenção ou tratamento de tauopatia
AU2018277981B2 (en) 2017-06-02 2021-04-08 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating spinocerebellar ataxia
SG11201911519UA (en) 2017-06-02 2020-01-30 Fujifilm Toyama Chemical Co Ltd AGENT FOR REDUCING AMOUNT OF AMYLOID ß PROTEIN
JP7227914B2 (ja) 2017-10-30 2023-02-22 富士フイルム富山化学株式会社 エモパミル結合タンパク質結合剤およびその利用
AU2019212170B2 (en) * 2018-01-24 2022-12-22 Ac Immune Sa Novel method of preparing an imaging compound
US20210041447A1 (en) * 2018-01-24 2021-02-11 Ac Immune Sa Azacarboline compounds for the detection of tau aggregates
EP3743423A1 (en) 2018-01-24 2020-12-02 AC Immune SA Gamma-carboline compounds for the detection of tau aggregates
EP3999182A1 (en) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268771A (en) 1968-03-15 1972-03-29 Glaxo Lab Ltd Azacarbazoles
WO2008132454A1 (en) * 2007-04-26 2008-11-06 Ge Healthcare Limited Carbolines and their use as imaging agents
US20110046378A1 (en) * 2008-02-14 2011-02-24 Siemens Medical Solutions Usa, Inc. Novel Imaging Agents for Detecting Neurological Dysfunction
ES2490867T3 (es) * 2008-12-19 2014-09-04 Bristol-Myers Squibb Company Inhibidores de carbazol y carbolina quinasas
WO2013176698A1 (en) * 2012-05-22 2013-11-28 Eli Lilly And Company Carboline and carbazole based imaging agents for detecting neurological dysfunction
WO2014194169A1 (en) * 2013-05-31 2014-12-04 The General Hospital Corporation Radiosynthesis of tau radiopharmaceuticals
US9774356B2 (en) * 2013-07-24 2017-09-26 Telefonaktiebolaget Lm Ericsson (Publ) Method and apparatus relating to reception of radio signals
AU2014333996B2 (en) * 2013-10-08 2018-03-15 F. Hoffmann-La Roche Ag Diazacarbazole derivatives as tau-pet-ligands
WO2015110263A1 (en) * 2014-01-21 2015-07-30 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyolid-like proteins

Also Published As

Publication number Publication date
JP2018503673A (ja) 2018-02-08
CN107207508A (zh) 2017-09-26
SG11201705727TA (en) 2017-08-30
US11312716B2 (en) 2022-04-26
US20180022748A1 (en) 2018-01-25
EA201791733A1 (ru) 2018-01-31
IL253381A0 (en) 2017-09-28
JP6579670B2 (ja) 2019-09-25
US20220213103A1 (en) 2022-07-07
EA036518B1 (ru) 2020-11-18
MX2017009505A (es) 2017-11-02
CN107207508B (zh) 2020-02-28
EP3253762B1 (en) 2021-05-05
CA2973648A1 (en) 2016-08-11
AU2016214537A1 (en) 2017-08-03
KR20170113607A (ko) 2017-10-12
BR112017016311A2 (pt) 2018-03-27
WO2016124508A1 (en) 2016-08-11
AU2016214537B2 (en) 2018-05-10
KR102621513B1 (ko) 2024-01-04
DK3253762T3 (da) 2021-07-19
IL253381B (en) 2020-10-29
EP3253762A1 (en) 2017-12-13
ES2875734T3 (es) 2021-11-11
US20210047326A1 (en) 2021-02-18
MY191590A (en) 2022-06-30
CA2973648C (en) 2023-09-26

Similar Documents

Publication Publication Date Title
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
NI201700096A (es) Derivados de 4h-pirrol[3, 2-c]piridin-4-ona
DOP2017000298A (es) Reguladores de nrf2
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CR20170564A (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4&#39; -difluorometilo como inhibidores de la replicación de arn de la influenza.
GT201400144A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO2019006673A2 (es) Polimorfos
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
CO2019006687A2 (es) Polimorfos
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
ECSP19089214A (es) Inhibidores de quinasa y usos de los mismos
DOP2016000312A (es) Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2
UY38031A (es) Hidroxiisoxazolinas y derivados de estos
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
CL2017000151A1 (es) Derivados de piridona
CL2018001493A1 (es) Nuevos derivados de fenilo
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen